Fax: (617) 632-4247
Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer†
A decision analysis
Version of Record online: 30 JUN 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 1, pages 258–267, 1 January 2012
How to Cite
Parikh, R. and Sher, D. J. (2012), Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer. Cancer, 118: 258–267. doi: 10.1002/cncr.26272
See editorial on pages 12-14, this issue.
- Issue online: 16 DEC 2011
- Version of Record online: 30 JUN 2011
- Manuscript Accepted: 11 APR 2011
- Manuscript Revised: 4 APR 2011
- Manuscript Received: 9 FEB 2011
- decision analysis;
- radical prostatectomy;
- external beam radiation;
- prostate cancer;
- high risk
Two evidence-based therapies exist for the treatment of high-risk prostate cancer (PCA): external-beam radiotherapy (RT) with hormone therapy (H) (RT + H) and radical prostatectomy (S) with adjuvant radiotherapy (S + RT). Each of these strategies is associated with different rates of local control, distant metastasis (DM), and toxicity. By using decision analysis, the authors of this report compared the quality-adjusted life expectancy (QALE) between men with high-risk PCA who received RT + H versus S + RT versus a hypothetical trimodality therapy (S + RT + H).
The authors developed a Markov model to describe lifetime health states after treatment for high-risk PCA. Probabilities and utilities were extrapolated from the literature. Toxicities after radiotherapy were based on intensity-modulated radiotherapy series, and patients were exposed to risks of diabetes, cardiovascular disease, and fracture for 5 years after completing H. Deterministic and probabilistic sensitivity analyses were performed to model uncertainty in outcome rates, toxicities, and utilities.
RT + H resulted in a higher QALE compared with S + RT over a wide range of assumptions, nearly always resulting in an increase of >1 quality-adjusted life year with outcomes highly sensitive to the risk of increased all-cause mortality from H. S + RT + H typically was superior to RT + H, albeit by small margins (<0.5 quality-adjusted life year), with results sensitive to assumptions about toxicity and radiotherapy efficacy.
For men with high-risk PCA, RT + H was superior to S + RT, and the result was sensitive to the risk of all-cause mortality from H. Moreover, trimodality therapy may offer local and distant control benefits that lead to optimal outcomes in a meaningful population of men. Cancer 2012;. © 2011 American Cancer Society.